...
首页> 外文期刊>Cancer chemotherapy and pharmacology. >Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity.
【24h】

Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity.

机译:S-1同期放化疗同时治疗老年和/或合并症病例的局部晚期头颈部鳞状细胞癌的可行性和毒性分析。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The aim of this study was to evaluate the feasibility and toxicity of concurrent chemoradiotherapy (CCRT) with S-1 in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) in elderly cases and/or cases with comorbidity. METHODS: Fifty eligible patients with stage III (15 cases) or stage IV (35 cases) SCCHN were treated with CCRT. Thirteen cases had an advanced age of over 75 years and 37 cases had comorbidity. Definitive radiotherapy was delivered up to a total dose of 66-70.2 Gy. The patients received two courses of oral S-1 (40 or 50 mg twice a day [80 or 100 mg/day]) for 2 weeks followed by 1 week of rest while receiving CCRT. RESULTS: All the patients received the planned radiotherapy and at least one course of S-1. Grade 3 mucositis occurred in 20% of the patients (10/50). Grade 3 neutropenia occurred in 12% (6/50) and leukocytopenia occurred in 6% (3/50) of the cases. Pathologically, the complete response rates were 93% in stage III and 54% in stage IV. CONCLUSION: Concurrent chemoradiotherapy with S-1 is a safe, well-tolerated and effective regimen for locally advanced SCCHN in elderly cases and/or cases with comorbidity.
机译:目的:本研究的目的是评估在老年人和/或合并症患者中,局部放疗的头颈部鳞状细胞癌(SCCHN)与S-1同步放化疗(CCRT)的可行性和毒性。方法:对50例符合条件的III期(15例)或IV期(35例)SCCHN患者进行CCRT治疗。年龄超过75岁的13例和合并症37例。最终放疗的总剂量达到66-70.2 Gy。患者接受CCRT的两个疗程的口服S-1(每天两次40或50 mg [80或100 mg /天]),持续2周,然后休息1周。结果:所有患者均接受了计划的放射治疗和至少一个S-1疗程。 20%的患者发生了3级粘膜炎(10/50)。 3级中性粒细胞减少症发生在12%(6/50),白细胞减少症发生在6%(3/50)。病理上,第三阶段的完全缓解率为93%,第四阶段为54%。结论:对于老年患者和/或合并症患者,S-1同时放化疗是局部晚期SCCHN的一种安全,耐受良好且有效的治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号